Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The acquisition expands scalable trial operations across real-world care settings
-
Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase 3 LEAP2MONO, le venglustat, administré...
-
Sanofi's investigational drug venglustat improved the neurologic symptoms of type 3 Gaucher disease, for which there are currently no approved therapies.
-
Austin, TX, USA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Spatial Biology Market Size, Trends and Insights By Molecular Technology...
-
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
-
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a...
-
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit solely focused on accelerating a cure for type 1 diabetes, announced the release of the 14th...
-
BGB Group strengthens pharma commercialization capabilities by integrating Hayden's payer and reimbursement expertise into its advisory practice.
-
Today Kneat announced that a global biopharma solutions leader selected Kneat to drive digital validation excellence.
-
SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...